Christopher A. Klebanoff, MD
Cellular Therapist & Early Drug Development Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
About Me
- Laboratory Head, Human Oncology and Pathogenesis Program (HOPP)
- Member Investigator, Center for Cell Engineering
I am a medical oncologist and translational researcher whose focus is on providing the best care possible to people with breast cancer. My dual role in the clinical setting and the laboratory allows me to work with my patients to develop more-effective, less-toxic therapies. I strongly believe that this is how we will change the future of cancer care.
Read more
The ability to use a patient’s own immune system as a form of cancer treatment — immunotherapy — is revolutionizing how we attack many cancers. My goal is to bring these advances to people with breast cancer, a disease for which we are still discovering immunotherapy’s full potential. To this end, I am a member of the Center for Cell Engineering and the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering, where I am involved in both clinical trials and laboratory research that aim to bring the most promising immunotherapies to our patients. My expertise is in cellular therapy and genetic engineering, immune-stimulating antibodies and hormones (also called cytokines), and cancer vaccines.
Like many others, my family has been impacted by cancer. I have firsthand experience with how devastating a cancer diagnosis can be, and this guides every interaction I have with my patients and their families. It’s my goal to provide them with a full understanding of the nature of their disease, the treatment options available, and the evidence that supports these options. I believe it’s critical to present what can be an overwhelming amount of information and medical jargon in a way that makes sense.
In addition to empowering my patients with knowledge and understanding, I also want to empower them by providing clear ways of accessing and communicating with me and other members of their care team throughout their treatment and follow-up care. I never want my patients to feel isolated or alone. This communication and collaboration helps us focus on making people feel physically better and confident that they are receiving a treatment plan tailored to their individual needs and goals.
A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.
An early drug development specialist tests new drugs to treat cancer. They have special training in research studies, known as clinical trials.
My Specialties
- Cancer Immunotherapy
- Cellular therapy
- Breast Medicine
Education
- MD, Emory University School of Medicine
Residencies
- The Johns Hopkins Hospital
Awards and Honors
- Fellows Award for Research Excellence, National Institutes of Health (2013)
- Outstanding Postdoctoral Fellow, National Cancer Institute (2011)
Fellowships
- National Cancer Institute
- National Institutes of Health
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Klebanoff sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med. 2016 Jan;22(1):26-36. PMID: 26735408
Klebanoff CA, Restifo NP. Customizing Functionality and Payload Delivery for Receptor-Engineered T Cells. Cell. 2016 Oct 6;167(2):304-306. PMID: 27716501
Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, Ramaswamy M, Roychoudhuri R, Ji Y, Eil RL, Sukumar M, Crompton JG, Palmer DC, Borman ZA, Clever D, Thomas SK, Patel S, Yu Z, Muranski P, Liu H, Wang E, Marincola FM, Gros A, Gattinoni L, Rosenberg SA, Siegel RM, Restifo NP. Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. J Clin Invest. 2016 Jan;126(1):318-34. PMID: 26657860
Read more
Visit PubMed for a full listing of Dr. Klebanoff’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Christopher A. Klebanoff discloses the following relationships and financial interests:
-
Achilles Therapeutics
Equity; Professional Services and Activities -
Affini-T Therapeutics
Equity; Intellectual Property Rights; Professional Services and Activities -
Aleta Biotherapeutics
Professional Services and Activities
-
Catamaran Bio, Inc.
Intellectual Property Rights; Professional Services and Activities -
Intima Bioscience, Inc.
Intellectual Property Rights -
Obsidian Therapeutics
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].